Connect With Us:
PRESS ROOM
ADAP Advocacy issued the following press releases:
ADAP Advocacy Honors World AIDS Day 2024 with a “Light for Hope”
World AIDS Day, designated on 1 December every year since 1988
WASHINGTON, D.C. - (December 1, 2024) - ADAP Advocacy today, on World AIDS Day, honored the lives lost to the epidemic by asking its supporters to ignite candles, which represent the light of life extinguished when a person dies. It is estimated over 22 million souls have been lost since 1981. The candles’ flames not only embody the collective hope for the future, but they also remember loved ones, neighbors, and colleagues lost to it.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Publishes Infographic Series on the 340B Program
Infographics analyze hospital revenues and executive compensation, compared to hospital charity care and patient medical debt
WASHINGTON, D.C. - (November 25, 2024) - ADAP Advocacy today, as part of its 340B Project, published an infographic series on the 340B Drug Pricing Program. The infographics highlight how under the program, hospital charity care is declining while medical debt is exploding despite hospital revenue growth and hospital CEO pay raises. The ADAP Advocacy-sponsored Ryan White Grantee 340B Patient Advisory Committee has increasingly focused on medical debt and its impact on patients living with chronic illnesses and rare diseases.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Launches Patient Perspectives Survey on Medical Debt
Medical Debt is the most common collection item on consumer credit reports
WASHINGTON, D.C. - (September 29, 2024) - ADAP Advocacy today, as part of its 340B Project, launched an online survey to assess patient perspectives and experiences with medical debt. The ADAP Advocacy-sponsored Ryan White Grantee 340B Patient Advisory Committee earlier this year voted unanimously to commission the online survey. It is estimated that over 100 million individuals in the United States have health care debt.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Unveils "Light for Hope" Candle for World AIDS Day 2024
MoonAmor Candle Co. commissioned to design commemorative candle
WASHINGTON, D.C. - (August 28, 2024) - ADAP Advocacy today unveiled a limited edition, commemorative "Light for Hope" candle for World AIDS Day 2024. MoonAmor Candle Co. was commissioned to design the candle, which embodies the solidarity of the people fighting to end the HIV/AIDS epidemic, as well as remembering those lost to it. On December 1st, ADAP Advocacy urges supporters in the United States to light the commemorative candles at 7:00 p.m. ET.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Shines Spotlight on 340B Covered Entities Executive Comp
The 340B Drug Pricing Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities
WASHINGTON, D.C. - (August 14, 2024) - ADAP Advocacy today, as part of its 340B Project and in collaboration with the Community Access National Network (CANN), published an extensive report on the 340B Drug Pricing Program and its impact on covered entities executive compensation. The report, titled – “The 340B Drug Pricing Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities” – found that annual revenues increased by an average of 824.32%, while executive compensation increased by an average of 231.51%.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Endorses Campaign, ‘340B: What About Me?’
Campaign raises awareness on how focus of the 340B Drug Pricing Program has shifted from helping patients to profiting healthcare providers
WASHINGTON, D.C. - (August 5, 2024) - ADAP Advocacy today, as part of its 340B Project, formally endorsed the ‘340B: What About Me?” awareness campaign launched last year by the Community Access National Network (CANN). The ADAP Advocacy-sponsored Ryan White Grantee 340B Patient Advisory Committee voted unanimously to endorse the campaign because of its focus on returning the 340B Drug Pricing Program to its original legislative intent: helping patients!
Download the Press Release:
PDF |
DOC
ADAP Advocacy Publishes Final Report for Patient Perspectives on Long-Acting Injectables
Comprehensive Report Offers Patient Access Considerations for Injectable HIV Therapies & Injectable HIV Pre-Exposure Prophylaxis
WASHINGTON, D.C. - (June 27, 2024) - ADAP Advocacy today, as part of its Long-Acting Injectables (LAIs) Project, published its final report and executive summary on patient perspectives from people living with HIV about approved LAIs medications for the treatment of HIV/AIDS, as well as their HIV-negative counterparts about HIV Pre-Exposure Prophylaxis (PrEP) injectables. The findings yield valuable insights to the barriers being faced by both populations.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Warns Fraudsters are Using Grindr to Buy HIV Meds
Gay dating App users are unknowingly jeopardizing patient safety by selling their prescription medications to fraudulent counterfeit drug rings
WASHINGTON, D.C. - (June 13, 2024) - ADAP Advocacy, in collaboration with the Partnership for Safe Medicines (PSM), today issued a safety alert warning Grindr’s users to stop selling their HIV and other medications on the popular gay dating App. Grindr, as well as potentially other dating Apps, are being used as a platform for fake user profiles operating under counterfeit drug rings to buy prescription medications. This seemingly innocent practice is not only illegal, but it is jeopardizing the drug supply chain and putting the health of patients at risk for health complications, severe illness, and even death.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Applauds Introduction of the 340B ACCESS Act
Leading National HIV Advocacy Organization Calling for 340B Reform Issues Statement
WASHINGTON, D.C. - (May 29, 2024) - ADAP Advocacy today enthusiastically endorsed the 340B ACCESS Act ("340B Affording Care for Communities & Ensuring a Strong Safety-net Act"), introduced by Representatives Larry Bucshon (IN-8), Earl L. "Buddy" Carter (GA-01), and Diana Harshbarger (TN-01). The growing chorus of patients, advocacy organizations, small healthcare clinics, drug manufacturers, news media editorial boards, healthcare economists, researchers and academics calling for reform to this vital safety net program has finally come full circle with the introduction of this comprehensive health reform legislation.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Releases 2023 Annual Report
Patient Advisory Committees Play Increasingly Important Advocacy Role
WASHINGTON, D.C. - (April 10, 2024) - ADAP Advocacy today released its 2023 Annual Report – which highlights the organization’s ongoing commitment to access, information and participation for patient advocacy designed to promote and protect the AIDS Drug Assistance Program ("ADAP"). The report is shared using an infographic format to capture the previous year’s highlights.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Announces Makeover of its Flagship ADAP Directory
Directory is a convenient online resource to access information and tools on AIDS Drugs Assistance Program for all US states and territories
WASHINGTON, D.C. - (March 20, 2024) - ADAP Advocacy today announced its flagship ADAP Directory has undergone a complete makeover. The re-launch continues to feature its user-friendly state and territorial directory of the Ryan White HIV/AIDS Program’s AIDS Drug Assistance Program (ADAP), while offering new patient-centric information and resources.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Announces 2024 Health Fireside Chats
Retreats designed to assemble key stakeholder groups to discuss pertinent issues facing people living with HIV/AIDS and other chronic health conditions
WASHINGTON, D.C. - (March 7, 2024) - ADAP Advocacy today announced the schedule for its 2024 Health Fireside Chats.
Download the Press Release:
PDF |
DOC
ADAP Advocacy is an Organizational Partner of SYNC 2024
National Conference to be held May 29th-31st in Arlington, VA
WASHINGTON, D.C. - (February 15, 2024) - ADAP Advocacy today announced it is a proud organizational partner of SYNChronicity 2024 (SYNC 2024), the Annual National Conference for HIV, HCV, STIs, Harm Reduction, and LGBTQ Health, to be held May 29th-31st in Arlington, Virginia.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Unveils Survey on Long-Acting Injectables for HIV Prevention
Survey Seeks Patient Perspectives from People Who are HIV-Negative on Long-Acting Injectables HIV Pre-Exposure Prevention
WASHINGTON, D.C. - (February 1, 2024) - ADAP Advocacy today, as part of its Long-Acting Injectables (LAIs) Project, launched an online survey to gain better patient perspectives from people who are HIV-negative about approved LAI medications for HIV Pre-Exposure Prophylaxis (PrEP). The online survey is open to people who are HIV-Negative and residing in the United States and its Territories.
Download the Press Release:
PDF |
DOC
ADAP Advocacy Aghast Over CA Governor's Proposed 2024-2025 Budget
State AIDS Drug Assistance Program would be raided by $500 million
WASHINGTON, D.C. - (January 16, 2024) - ADAP Advocacy today issued the following statement by CEO Brandon M. Macsata:
"ADAP Advocacy is deeply concerned over California Governor Gavin Newsom’s proposed 2024-2025 budget because it attempts to balance the state’s growing budget deficit by exploiting safety net programs, including the State AIDS Drug Assistance Program (ADAP). A proposed budgetary loan of $500 million from the state’s ADAP Rebate Fund to the General Fund sets a very dangerous precedent in a progressive state, but it represents the latest attempt by politicians to raid ADAP-related funds for things other than providing care and treatment to people living with HIV/AIDS. We’ve already witnessed attempts at the federal level to divert ADAP funding from HIV care to HIV prevention with the greed-drive Ryan White PrEP Availability Act, as well as at the state level, such as New York, trying to manipulate already limited HIV-related funding. ADAP Advocacy urges California lawmakers to oppose any financial shenanigans misusing funds designated for the AIDS Drug Assistance Program."
Download the Press Release:
PDF |
DOC
ADAP Advocacy Blasts FDA on Florida’s Drug Importation Approval
Federal agency’s approval of the risky drug importation plan potentially puts the health of people living with HIV at risk
WASHINGTON, D.C. - (January 5, 2024) - ADAP Advocacy today issued the following statement by CEO Brandon M. Macsata:
“ADAP Advocacy is disturbed by the U.S. Food & Drug Administration’s deeply flawed decision to approve Florida’s plan to import prescription drugs from Canada. This policy is a particularly acute threat to people living with HIV in the United States and Canada since the list of drugs Florida intends to import includes a disproportionate number of treatments for HIV. Additionally, the safety of HIV medicine has already been in question following one of the largest counterfeiting schemes in our nation’s history. Given Canada’s expressed concerns about participating in importation plans, we are worried patients in Florida will now be at even greater risk for counterfeits. We urge the FDA to reconsider approving Florida's Canadian drug importation program.”
Download the Press Release:
PDF |
DOC
Past Press Releases: [2023] · [2022] · [2021] · [2020] · [2019] · [2018] · [2017] · [2016] · [2015] · [2014] · [2013] · [2012] · [2011] · [2010] · [2009]
